Dr. Bourla’s commentary came two days after U.S. Trade Representative Katherine Tai announced the U.S. will support waiving intellectual property protections for COVID-19 vaccines to expedite global vaccine production as the pandemic continues to rage in India and South America.
He said Pfizer’s COVID-19 vaccine manufacturing was hindered by a scarcity of 280 specialized raw materials sourced from 19 different countries, an issue he fears will be greatly exacerbated if other companies are welcome to compete for them.
“Right now, virtually every single gram of raw material produced is shipped immediately into our manufacturing facilities and is converted immediately and reliably to vaccines that are shipped immediately around the world,” Dr. Bourla wrote.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
